Effect of Linking Data Using Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus
A Primary Care-Based, Prospective, Multicenter, Cluster-Randomized, Pragmatic Clinical Trials to Determine the Effect of Linking Data With Investigators When Using the Electronic Health Record-Linked Smartphone Application, 'Well Check', on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: NaRi Kim
- Phone Number: 82-10-6611-7051
- Email: nrkim209@daewoong.co.kr
Study Locations
-
-
-
Seoul, South Korea
- Kyung Hee University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults aged 19 years and older.
Patients with Type 2 diabetes who are scheduled to receive initial treatment with Enavogliflozin or Enavogliflozin Extended-Release Tablets based on the attending physician's medical judgment, within the following insurance coverage ranges:
- Enavogliflozin monotherapy
- Combination therapy of Enavogliflozin with two agents (metformin)
- Combination therapy of Enavogliflozin with three agents (metformin + DPP-4 inhibitor)
- Individuals who have received detailed explanation and have understood the nature of the observational study and the investigational drug, and have provided written consent to participate voluntarily in the observational study and to comply with subject precautions during the study period.
Exclusion Criteria:
- Individuals with diabetes other than Type 2 diabetes (Type 1 diabetes, diabetic ketoacidosis, gestational diabetes, etc.).
Individuals who are contraindicated for Enavogliflozin or Enavogliflozin Extended-Release Tablets based on the approved indications:
- Patients with a history of hypersensitivity reactions to the components of Enavogliflozin or Enavogliflozin Extended-Release Tablets
- Patients with an eGFR (estimated Glomerular Filtration Rate) less than 30 mL/min/1.73m2, end-stage renal disease, or undergoing dialysis
- Patients with moderate to severe hepatic impairment (AST or ALT > 3 times the upper limit of normal, Total Bilirubin > 2 times the upper limit of normal, hepatitis or hepatic failure)
- Patients classified as NYHA (New York Heart Association) class III or IV
- Patients initiating treatment with Enavogliflozin or Enavogliflozin Extended-Release Tablets at enrollment with an eGFR of less than 60ml/min/1.73m2.
- Patients with unstable weight due to treatment with obesity drugs or weight loss medications within 3 months prior to enrollment or other treatments (surgery, dietary therapy, etc.).
- Pregnant and lactating women.
- Individuals currently participating in another clinical trial and receiving investigational drugs or investigational medical devices.
- Other individuals deemed unsuitable for participation in the observational study based on the investigator's (attending physician's) judgment.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with type 2 diabetes
mobile application "WellCheck" use
|
Physician-managed "WellCheck" use
self-managed "WellCheck" use
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in glycated hemoglobin (HbA1c) levels
Time Frame: 24 weeks
|
change in glycated hemoglobin (HbA1c) levels at 24 weeks from baseline
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in glycated hemoglobin (HbA1c) levels
Time Frame: 6 weeks
|
change in glycated hemoglobin (HbA1c) levels at 6 weeks post-baseline
|
6 weeks
|
|
change in glycated hemoglobin (HbA1c) levels
Time Frame: 12 weeks
|
change in glycated hemoglobin (HbA1c) levels at 12 weeks post-baseline
|
12 weeks
|
|
change in glycated hemoglobin (HbA1c) levels
Time Frame: 18 weeks
|
change in glycated hemoglobin (HbA1c) levels at 18 weeks post-baseline
|
18 weeks
|
|
the change in fasting plasma glucose (FPG)
Time Frame: 6 weeks
|
the change in fasting plasma glucose (FPG) at 6 weeks post-baseline
|
6 weeks
|
|
the change in fasting plasma glucose (FPG)
Time Frame: 12 weeks
|
the change in fasting plasma glucose (FPG) at 12 weeks post-baseline
|
12 weeks
|
|
the change in fasting plasma glucose (FPG)
Time Frame: 18 weeks
|
the change in fasting plasma glucose (FPG) at 18 weeks post-baseline
|
18 weeks
|
|
the proportion of participants achieving HbA1c less than 7% or 6.5%
Time Frame: 6 weeks
|
the proportion of participants achieving HbA1c less than 7% or 6.5% at 6 weeks post-baseline
|
6 weeks
|
|
the proportion of participants achieving HbA1c less than 7% or 6.5%
Time Frame: 12 weeks
|
the proportion of participants achieving HbA1c less than 7% or 6.5% at 12 weeks post-baseline
|
12 weeks
|
|
the proportion of participants achieving HbA1c less than 7% or 6.5%
Time Frame: 18 weeks
|
the proportion of participants achieving HbA1c less than 7% or 6.5% at 18 weeks post-baseline
|
18 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DW_ODNENV_DB_01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.